Expression of microRNAs in basal cell carcinoma. 2012

M Sand, and M Skrygan, and D Sand, and D Georgas, and S A Hahn, and T Gambichler, and P Altmeyer, and F G Bechara
Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum, 44791 Bochum, Germany. michael.sand@ruhr-uni-bochum.de

BACKGROUND Perturbations in the expression profiles of microRNAs (miRNAs) have been reported for a variety of different cancers. Differentially expressed miRNAs have not been systematically evaluated in basal cell carcinoma (BCC) of the skin. OBJECTIVE To initiate a microarray-based miRNA profiling study to identify specific miRNA candidates that are differentially expressed in BCC. METHODS Patients with BCC (n = 7) were included in this study. Punch biopsies were harvested from the tumour centre (lesional, n = 7) and from adjacent nonlesional skin (intraindividual control, n = 7). Microarray-based miRNA expression profiles were obtained on an Agilent platform using miRBase 16 screening for 1205 Homo sapiens (hsa)-miRNA candidates. To validate the microarray data, the expression of seven dysregulated miRNAs was measured by TaqMan quantitative real-time reverse transcription polymerase chain reaction. RESULTS We identified 16 significantly upregulated (hsa-miR-17, hsa-miR-18a, hsa-miR-18b, hsa-miR-19b, hsa-miR-19b-1*, hsa-miR-93, hsa-miR-106b, hsa-miR-125a-5p, hsa-miR-130a, hsa-miR-181c, hsa-miR-181c*, hsa-miR-181d, hsa-miR-182, hsa-miR-455-3p, hsa-miR-455-5p and hsa-miR-542-5p) and 10 significantly downregulated (hsa-miR-29c, hsa-miR-29c*, hsa-miR-139-5p, hsa-miR-140-3p, hsa-miR-145, hsa-miR-378, hsa-miR-572, hsa-miR-638, hsa-miR-2861 and hsa-miR-3196) miRNAs in BCC compared with nonlesional skin. Data mining revealed connections to many tumour-promoting pathways, such as the Hedgehog and the mitogen-activated protein kinase/extracellular signal-regulated kinase signalling cascades. CONCLUSIONS This study identified several miRNA candidates that may play a role in the molecular pathogenesis of BCC.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002280 Carcinoma, Basal Cell A malignant skin neoplasm that seldom metastasizes but has potentialities for local invasion and destruction. Clinically it is divided into types: nodular, cicatricial, morphaic, and erythematoid (pagetoid). They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck area and the remaining 15% on the trunk and limbs. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1471) Carcinoma, Basal Cell, Pigmented,Epithelioma, Basal Cell,Rodent Ulcer,Ulcer, Rodent,Basal Cell Carcinoma,Basal Cell Carcinomas,Basal Cell Epithelioma,Basal Cell Epitheliomas,Carcinomas, Basal Cell,Epitheliomas, Basal Cell,Rodent Ulcers,Ulcers, Rodent
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old
D012334 RNA, Neoplasm RNA present in neoplastic tissue. Neoplasm RNA
D012878 Skin Neoplasms Tumors or cancer of the SKIN. Cancer of Skin,Skin Cancer,Cancer of the Skin,Neoplasms, Skin,Cancer, Skin,Cancers, Skin,Neoplasm, Skin,Skin Cancers,Skin Neoplasm
D015536 Down-Regulation A negative regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins. Receptor Down-Regulation,Down-Regulation (Physiology),Downregulation,Down Regulation,Down-Regulation, Receptor

Related Publications

M Sand, and M Skrygan, and D Sand, and D Georgas, and S A Hahn, and T Gambichler, and P Altmeyer, and F G Bechara
January 2021, Journal of immunology research,
M Sand, and M Skrygan, and D Sand, and D Georgas, and S A Hahn, and T Gambichler, and P Altmeyer, and F G Bechara
December 1992, The British journal of dermatology,
M Sand, and M Skrygan, and D Sand, and D Georgas, and S A Hahn, and T Gambichler, and P Altmeyer, and F G Bechara
December 2004, The American Journal of dermatopathology,
M Sand, and M Skrygan, and D Sand, and D Georgas, and S A Hahn, and T Gambichler, and P Altmeyer, and F G Bechara
May 2014, Archives of dermatological research,
M Sand, and M Skrygan, and D Sand, and D Georgas, and S A Hahn, and T Gambichler, and P Altmeyer, and F G Bechara
January 2016, Anais brasileiros de dermatologia,
M Sand, and M Skrygan, and D Sand, and D Georgas, and S A Hahn, and T Gambichler, and P Altmeyer, and F G Bechara
November 1997, The British journal of dermatology,
M Sand, and M Skrygan, and D Sand, and D Georgas, and S A Hahn, and T Gambichler, and P Altmeyer, and F G Bechara
June 2002, Experimental dermatology,
M Sand, and M Skrygan, and D Sand, and D Georgas, and S A Hahn, and T Gambichler, and P Altmeyer, and F G Bechara
January 2013, Journal of the European Academy of Dermatology and Venereology : JEADV,
M Sand, and M Skrygan, and D Sand, and D Georgas, and S A Hahn, and T Gambichler, and P Altmeyer, and F G Bechara
May 2016, Epigenomics,
M Sand, and M Skrygan, and D Sand, and D Georgas, and S A Hahn, and T Gambichler, and P Altmeyer, and F G Bechara
January 1994, British journal of cancer,
Copied contents to your clipboard!